SRSara D. Reis

Sara D. Reis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sara D. Reis has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeting the proteostasis network in Huntington’s disease

    by Tânia R. Soares, Sara D. Reis, Brígida R. Pinho, Michael R. Duchen, Jorge M.A. Oliveira


  • Open Access

    Mitochondrial superoxide generation induces a parkinsonian phenotype in zebrafish and huntingtin aggregation in human cells

    by Brígida R. Pinho, Sara D. Reis, Richard C. Hartley, Michael P. Murphy, Jorge M.A. Oliveira


  • Influence of seed priming with iron and/or zinc in the nucleolar activity and protein content of bread wheat

    by Ana Carvalho, Sara Reis, Ivo Pavia, José Eduardo Lima-Brito

    Seed priming with iron (Fe) and/or zinc (Zn) can overcome the reduced availability of these micronutrients in soils and crops, but suitable dosages should be predetermined. Nucleolus responds to stress, such as cytotoxicity, with alterations perceivable by cytogenetic analyses. This work intends to study how seed priming with Fe and/or Zn affects the nucleolar activity in roots and the total soluble protein content in the flour of bread wheat cv. ‘Jordão’. Seven priming treatments with 0 mg L−1 to 8 mg L−1 of Fe and/or Zn were performed. In all treatments, each metaphase cell presented a maximum of six nucleolar organizer regions positively stained with silver nitrate (Ag-NORs). Also, a maximum number of six nucleoli per nucleus were observed in all treatments, except in the hydroprimed seeds (used as control) that showed a maximum of five nucleoli, probably due to nucleolar fusion. Irregular interphases were frequent in treatments with the highest dosage of micronutrients (8 mg L−1 Fe and/or 8 mg L−1 Zn). The nucleolar area reduced (p < 0.001) as the number of nucleoli increased, and it was lower in treatments with a combination of Fe and Zn. However, the combinations of Fe and Zn showed the highest concentrations of total soluble protein (p ≤ 0.001). Although a reduced nucleolar area represents low ribosomal RNA gene transcription and ribosomal production, the significant increase of the number of nucleoli in the seeds primed with Fe and Zn enhanced the total soluble protein content as compared to the hydroprimed seeds (control) probably due to an increase of nucleolar surface-to-volume ratio that improved the protein synthesis. Overall, this work revealed that priming of bread wheat seeds with suited dosages of Fe and Zn can improve the nutritional value of flour, and the nucleolar number, morphology, and area can be useful biomarkers in cytotoxicity studies.


  • A19 Pharmacological modulation of HSP70 in cellular models of huntington’s disease

    by Sara D Reis, Liliana M Almeida, Brígida R Pinho, Jorge Ma Oliveira

    Background Huntington’s disease (HD) is a protein misfolding disorder involving a mutant form of the huntingtin protein (Htt) with a polyglutamine expansion. Heat shock proteins (Hsp) are key therapeutic targets in protein misfolding diseases given their role in protein folding, aggregation, and degradation. YM-1 is an Hsp70 modulator (ATPase domain inhibitor) which was found protective in the polyglutamine disorder SBMA. However, given that the consequences of modulating a specific Hsp seem to depend on the nature of the client protein and the drug pharmacodynamics, it remains uncertain whether YM-1 might be protective in HD. Aims Assess the effects of YM-1 on Htt proteostasis. Methods PC12 cells with inducible full-length Htt(Q23/Q145); U2OS cells transfected with N-terminal GFP-Htt(Q23/Q74). Western Blot and immunoprecipitation were used to determine the levels of Htt, Hsp and their interaction. Htt aggregation was monitored by fluorescence microscopy. Results Concerning full-length Htt, treatment with YM-1 alone decreased mutant Htt (mHtt) in PC12 cells, without altering the levels of wild-type Htt. The effect of YM-1 was potentiated by heat shock conditions (HS; 42°C, 1 hour), leading to higher decreases in mHtt than HS alone. Since HS increased levels of Hsp70, these results are consistent with an Hsp70-dependent effect of YM-1. Concerning aggregation of N-terminal Htt, treatment with YM-1 increased the proportion of cells with mHtt aggregates. Conclusions: These results suggest that YM-1 alters mHtt proteostasis in an Hsp70-dependent manner, decreasing levels of full-length mHtt, possibly by enhancing its Hsp70-mediated degradation, and increasing aggregation of N-terminal mHtt, possibly by affecting the formation of Hsp70/40/110 disaggregation complex. Acknowledgments: Fundação para a Ciência e a Tecnologia P2020-PTDC/NEU-NMC/0412/2014, POCI-01-0145-FEDER-016577, 3599-PPCDT, UID/QUI/50006/2013, PD/BD/113567/2015, SFRH/BPD/102259/2014.

  • Modulation of Molecular Chaperones in Huntington’s Disease and Other Polyglutamine Disorders

    by Sara D. Reis, Brígida R. Pinho, Jorge M. A. Oliveira

    Polyglutamine expansion mutations in specific proteins underlie the pathogenesis of a group of progressive neurodegenerative disorders, including Huntington’s disease, spinal and bulbar muscular atrophy, dentatorubral-pallidoluysian atrophy, and several spinocerebellar ataxias. The different mutant proteins share ubiquitous expression and abnormal proteostasis, with misfolding and aggregation, but nevertheless evoke distinct patterns of neurodegeneration. This highlights the relevance of the full protein context where the polyglutamine expansion occurs and suggests different interactions with the cellular proteostasis machinery. Molecular chaperones are key elements of the proteostasis machinery and therapeutic targets for neurodegeneration. Here, we provide a focused review on Hsp90, Hsp70, and their co-chaperones, and how their genetic or pharmacological modulation affects the proteostasis and disease phenotypes in cellular and animal models of polyglutamine disorders. The emerging picture is that, in principle, Hsp70 modulation may be more amenable for long-term treatment by promoting a more selective clearance of mutant proteins than Hsp90 modulation, which may further decrease the necessary wild-type counterparts. It seems, nevertheless, unlikely that a single Hsp70 modulator will benefit all polyglutamine diseases. Indeed, available data, together with insights from effects on tau and alpha-synuclein in models of Alzheimer’s and Parkinson’s diseases, indicates that Hsp70 modulators may lead to different effects on the proteostasis of different mutant and wild-type client proteins. Future studies should include the further development of isoform selective inhibitors, namely to avoid off-target effects on Hsp in the mitochondria, and their characterization in distinct polyglutamine disease models to account for client protein-specific differences.


  • Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson’s disease

    by Brígida R. Pinho, Sara D. Reis, Pedro Guedes-Dias, Ana Leitão-Rocha, Clara Quintas, Patrícia Valentão, Paula B. Andrade, Miguel M. Santos, Jorge M.A. Oliveira


  • Open Access

    Bone Anabolic Effects of Soluble Si: In Vitro Studies with Human Mesenchymal Stem Cells and CD14+ Osteoclast Precursors

    by J Costa-Rodrigues, S Reis, A Castro, M H Fernandes

    Silicon (Si) is indispensable for many cellular processes including bone tissue metabolism. In this work, the effects of Si on human osteogenesis and osteoclastogenesis were characterized. Human mesenchymal stem cells (hMSC) and CD14+ stem cells, as osteoblast and osteoclast precursors, were treated with a wide range of Si concentrations, covering the physiological plasma levels. Si promoted a dose‐dependent increase in hMSC proliferation, differentiation, and function, at levels similar to the normal basal plasma levels. Additionally, a decrease in the expression of the osteoclastogenic activators M‐CSF and RANKL was observed. Also, Si elicited a decrease in osteoclastogenesis, which became significant at higher concentrations, as those observed after meals. Among the intracellular mechanisms studied, an upregulation of MEK and PKC signalling pathways was observed in both cell types. In conclusion, Si appears to have a direct positive effect on human osteogenesis, at basal plasma levels. On the other hand, it also seemed to be an inhibitor of osteoclastogenesis, but at higher concentrations, though yet in the physiological range. Further, an indirect effect of Si on osteoclastogenesis may also occur, through a downregulation of M‐CSF and RANKL expression by osteoblasts. Thus, Si may be an important player in bone anabolic regenerative approaches.


  • Open Access

    Dose‐dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity

    by João Costa‐Rodrigues, Sara Reis, Sónia Teixeira, Sandra Lopes, Maria H. Fernandes

    Proton pump inhibitors (PPIs), a class of molecules that are used to decrease gastric acid production, might have adverse effects on bone metabolism. The aim of this study was to characterize the concentration‐dependent and time‐dependent effects of three PPIs (omeprazole, esomeprazole, and lansoprazole) on human osteoclast precursor cells isolated from peripheral blood, and on human mesenchymal stem cells (osteoblast precursors). Cell cultures were characterized for total protein content, apoptosis, and several osteoclastic/osteoblastic features, and also for the involvement of some intracellular signaling pathways. PPIs caused a dose‐dependent decrease in cellular density, which correlated with an increase in the apoptosis rate, effects that became statistically significant at concentrations ≥ 10−5 m. They also inhibited phenotype‐related gene expression and functional parameters. For both cell types, cellular function, i.e. osteoclastic resorption and the formation of mineralized deposits by osteoblastic cells, was more affected than proliferation‐related parameters. The three PPIs showed similar qualitative and quantitative effects, but displayed some differences in the underlying intracellular signaling pathways. These results suggest that PPIs might have a direct deleterious effect on bone cells, with the possibility of decreased bone turnover.


  • Inhibition of osteoclastogenesis by proton pump inhibitors on co-cultures of human osteoclasts and breast cancer cells

    by Sara Reis, Maria Fernandes, Joao Costa-Rodrigues

    Proton pump inhibitors (PPIs) are a class of drugs particularly used in gastric disorders. They promote a decrease on gastric acid secretion by inhibiting the H+/K+ ATPases. Osteoclasts are cells specialized in bone resorption by H+ translocation to the bone surface. Thus, PPIs might be regarded as potential tools to modulate osteoclast resorption activity, particularly in conditions that are associated with a hyperactivation of osteoclasts, like it happens, in bone osteolytic metastasis. Breast cancer is one of the most frequent tumours that originate bone osteolytic metastasis. In this context, this work intended to characterize the effects of three PPIs on human osteoclastogenesis in co-cultures of human osteoclasts and breast cancer cells. Osteoclastic precursors were isolated from human peripheral blood and were co-cultured with two different breast cancer cell lines (T47D and SK-BR-3). Cell cultures were treated with a concentration range (10−7 to 10−3 M) of omeprazole, esomeprazole and lansoprazole. Cell cultures were characterized throughout a 21-day period for total protein content, tartarate-resistant acid phosphatase (TRAP) activity, TRAP+ multinucleated cells and the presence of cells with actin rings and expressing vitronectin and calcitonin receptors. The presence of breast cancer cells, particularly T47D cells, greatly induced osteoclastogenesis. The tested PPIs caused a dose-dependent inhibition of osteoclast development. The osteoclastogenic inhibition was verified at levels higher than 10−6 M for the three PPIs. Although the highest concentrations seemed to be toxic for osteoclastic cells, the inhibition observed at lower levels appeared to result from specific effects on the osteoclasts, rather than to a significant decrease on the cellular viability. Taken together, PPIs had the ability to decrease human osteoclastogenesis, when osteoclastic precursors were co-cultured with breast cancer cells. Understanding the subjacent mechanisms can open new perspectives in the utilization of such compounds in pathological conditions characterized by a hyperactivation of osteoclastic cells.

  • Osteoclastogenic modulation by silicon: Cellular and molecular mechanisms

    by J. Costa-Rodrigues, S. Reis, M.H. Fernandes